TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20350164

Group type: EXPERIMENTAL
Intervention: Fractional-dose IPV (0.1 mL, or 1/5 of a full dose) given intradermally
Number of subjects: 471

Group type: COMPARATOR
Intervention: Full-dose IPV given intramuscularly
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 471
Study: 18714060

Group type: EXPERIMENTAL
Intervention: Silver-coated endotracheal tube
Number of subjects: 2003

Group type: COMPARATOR
Intervention: Uncoated endotracheal tube
Number of subjects: 2003
Study: 15939850

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Incentive spirometry (IS)
Number of subjects: 18
Study: 12709724

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 200 mg twice daily for 10 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 400 mg twice daily for 14 days
Number of subjects: 30
Study: 10608477

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Enalapril 10 mg twice daily
Number of subjects: 25
Study: 7726133

Group type: EXPERIMENTAL
Intervention: Nephelometric method
Number of subjects: 330

Group type: COMPARATOR
Intervention: Hemolytic inhibition assay
Number of subjects: 330
Study: 1971597

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Covered corridor walking test (Control)
Number of subjects: 0
Study: 7402804

Group type: EXPERIMENTAL
Intervention: Home visits starting prenatally (Group A)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Home visits starting at six weeks postpartum (Group B)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No home visits (Group C)
Number of subjects: 115
Study: 30922285

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention combining participatory ergonomics, case management, and health promotion.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occupational health care as usual (Control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention.
Number of subjects: 0
Study: 28818733

Group type: EXPERIMENTAL
Intervention: Childhood trauma exposure
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 56
Study: 26790793

Group type: EXPERIMENTAL
Intervention: Systemic Tranexamic Acid (TXA) 15 mg/kg before and 10 mg/kg 1 hour after surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (TXA) 2 g
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no TXA applied)
Number of subjects: 90
Study: 23168135

Group type: EXPERIMENTAL
Intervention: Backfill with hydroxyapatite-calcium triphosphate (HCT) biphasic compound
Number of subjects: 40

Group type: COMPARATOR
Intervention: No backfill (Control)
Number of subjects: 40
Study: 22073137

Group type: EXPERIMENTAL
Intervention: IPTc delivered by village health workers (VHWs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IPTc delivered by outpatient department (OPD) nurses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IPTc delivered by EPI nurses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IPTc delivered by VHWs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IPTc delivered by facility-based nurses
Number of subjects: 12

Group type: COMPARATOR
Intervention: VHWs
Number of subjects: 12
Study: 19926574

Group type: EXPERIMENTAL
Intervention: HPV L1+ cases
Number of subjects: 187

Group type: COMPARATOR
Intervention: HPV L1- cases
Number of subjects: 187
Study: 16990664

Group type: EXPERIMENTAL
Intervention: GAD65 antibody response
Number of subjects: 36
Study: 12809069

Group type: EXPERIMENTAL
Intervention: Parenteral piracetam treatment
Number of subjects: 193

Group type: COMPARATOR
Intervention: Traditional meprobamat therapy
Number of subjects: 193
Study: 11014392

Group type: EXPERIMENTAL
Intervention: S-Caine patch coupled with a controlled heat-aided drug delivery (CHADD) patch
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9483483

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate therapy (Group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No magnesium treatment (Group II)
Number of subjects: 50
Study: 8620676

Group type: EXPERIMENTAL
Intervention: Zileuton 200 to 800mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: N-dehydroxylated metabolite of zileuton
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glucuronide metabolites of zileuton
Number of subjects: 16
Study: 2751854

Group type: EXPERIMENTAL
Intervention: Ranitidine (H2 antagonist)
Number of subjects: 0
Study: 326482

Group type: EXPERIMENTAL
Intervention: Practolol (dose up to 800 mg daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Practolol (in controlled double-blind trial with placebo)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Practolol (in exercise tolerance tests)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Long-term administration of practolol
Number of subjects: 53
Study: 31860328

Group type: COMPARATOR
Intervention: Standard 6‐month course of tuberculosis treatment (180 days), dosed every other day (90 doses)
Number of subjects: 780
Study: 31775800

Group type: COMPARATOR
Intervention: Dietary weight loss intervention
Number of subjects: 439

Group type: COMPARATOR
Intervention: Diet + exercise intervention
Number of subjects: 439

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Control group (no lifestyle change)
Number of subjects: 439
Study: 30380221

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg · kg⁻¹ loading dose for 10 min, followed by 0.7 μg · kg⁻¹ · hr⁻¹ maintenance)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Fentanyl (2 μg · kg⁻¹ loading dose, followed by 1-2 μg · kg⁻¹ · hr⁻¹ maintenance)
Number of subjects: 37
Study: 25882743

Group type: EXPERIMENTAL
Intervention: Phosphatidylethanol (PEth)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Carbohydrate-deficient transferrin (CDT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Traditional alcohol markers (including MCV, GGT, AST, ALT)
Number of subjects: 44
Study: 24728035

Group type: EXPERIMENTAL
Intervention: FOLFIRI followed by docetaxel and cisplatin
Number of subjects: 1100

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 1100
Study: 21643812

Group type: EXPERIMENTAL
Intervention: Atorvastatin (intensive lipid-lowering therapy for 6 months)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Pravastatin (moderate lipid-lowering therapy for 6 months)
Number of subjects: 76
Study: 19026406

Group type: EXPERIMENTAL
Intervention: Reinforcement for tic absence on a 10‐s fixed interval schedule in the presence of a purple light
Number of subjects: 10

Group type: COMPARATOR
Intervention: Instructions to suppress tics in the presence of an orange light without reinforcement
Number of subjects: 10

Group type: COMPARATOR
Intervention: No instructions to suppress tics in the presence of two non-illuminated lights
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Presence of purple light
Number of subjects: 10

Group type: COMPARATOR
Intervention: Presence of orange light
Number of subjects: 10

Group type: COMPARATOR
Intervention: Neither light illuminated
Number of subjects: 10
Study: 17301737

Group type: EXPERIMENTAL
Intervention: Single dose of 2.5 mg tibolone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Multiple doses of tibolone (placebo, 0.3, 0.625, 1.25, or 2.5 mg/day for 26 cycles of 28 days)
Number of subjects: 23
Study: 15333300

Group type: EXPERIMENTAL
Intervention: Parent-focused preschool child obesity intervention
Number of subjects: 0
Study: 11304601

Group type: EXPERIMENTAL
Intervention: EMLA cream 1.5 g/10 cm2 applied for 2 to 5 hours
Number of subjects: 403

Group type: COMPARATOR
Intervention: Infiltrated lidocaine
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: EMLA cream 3 g/10 cm2
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Adverse events (EMLA cream)
Number of subjects: 403
Study: 9356540

Group type: EXPERIMENTAL
Intervention: Nutrition education program designed to lower plasma cholesterol through dietary modifications
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (children with a stronger family history of CAD)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Apo E phenotype and Lp(a) measurements
Number of subjects: 125
Study: 1279611

Group type: EXPERIMENTAL
Intervention: Verapamil (120-mg thrice daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem (60-mg thrice daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 8
Study: 2936269

Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Papaveretum 0.4 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyoscine 0.008 mg/kg
Number of subjects: 0
Study: 30336685

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation of 2000 IU/d
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29396643

Group type: EXPERIMENTAL
Intervention: C31G (group A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Alcohol-free CHX 0.12% (group B)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Alcohol-based CHX 0.12% (group C)
Number of subjects: 42
Study: 26706023

Group type: EXPERIMENTAL
Intervention: Whole-grain wheat-based diet
Number of subjects: 54

Group type: COMPARATOR
Intervention: Refined cereal products (Control)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Whole-grain wheat-based diet (with high fasting propionate changes)
Number of subjects: 54
Study: 25179672

Group type: EXPERIMENTAL
Intervention: Web-based intervention (WBI) for concerned partners (CPs) of service members with alcohol misuse; 4 sessions, adapted from the Community Reinforcement and Family Training (CRAFT) intervention.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed-web based intervention (delayed-WBI) for concerned partners (CPs) of service members with alcohol misuse.
Number of subjects: 100
Study: 22395587

Group type: EXPERIMENTAL
Intervention: 8% and 10% topical sulfur ointment applied for a single day (24 hours)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 8% and 10% topical sulfur ointment applied for three successive nights
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 8% and 10% topical sulfur ointment applied for three successive days
Number of subjects: 97

Group type: COMPARATOR
Intervention: Comparison of three groups (single day, three nights, three days)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Group A (single day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Group B (three nights)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Group C (three days)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Side effects of 8% and 10% sulfur
Number of subjects: 97
Study: 19965971

Group type: EXPERIMENTAL
Intervention: Combination of heparin and aspirin
Number of subjects: 334

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 334
Study: 16735113

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 micro g bd
Number of subjects: 233

Group type: COMPARATOR
Intervention: Budesonide (BUD) 200 micro g bd
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Budesonide (BUD)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Both FP and BUD
Number of subjects: 233
Study: 15952261

Group type: EXPERIMENTAL
Intervention: Proactive interference from previous lists in a speeded-recognition task
Number of subjects: 0
Study: 12505249

Group type: EXPERIMENTAL
Intervention: High-vegetable, low-fat diet intervention with intensive telephone counseling, cooking classes, and print materials to encourage dietary changes.
Number of subjects: 3088

Group type: COMPARATOR
Intervention: Comparison group (control group).
Number of subjects: 3088
Study: 9863300

Group type: EXPERIMENTAL
Intervention: Beta-interferon (subcutaneous or intramuscular administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0
Study: 8705152

Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerin 0.3 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerin 0.5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerin 0.75 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerin 1.0 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study: 2205610

Group type: COMPARATOR
Intervention: Jobst pressure garments
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tubigrip pressure garments
Number of subjects: 110
Study: 7033016

Group type: EXPERIMENTAL
Intervention: Benzbromarone 100 mg daily
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Probenecid 1000 mg daily
Number of subjects: 6

Group type: COMPARATOR
Intervention: Allopurinol 300 mg daily
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30794093

Group type: EXPERIMENTAL
Intervention: Driving-based interactive video games (DBIVG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional therapy (CT) + Driving-based interactive video games (DBIVG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional therapy (CT) + Treadmill walking training
Number of subjects: 24
Study: 31658725

Group type: EXPERIMENTAL
Intervention: 40 mg iron daily
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: 80 mg iron daily
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: 20 mg iron daily
Number of subjects: 791
Study: 29202732

Group type: EXPERIMENTAL
Intervention: Targeted kyphosis-specific exercise and posture training program, delivered by a physical therapist, 1 hour, twice a week for 3 months.
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waitlist control for 3 months before receiving the delayed intervention.
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Targeted kyphosis-specific exercise and posture training program.
Number of subjects: 112
Study: 25324445

Group type: EXPERIMENTAL
Intervention: Paracetamol and ondansetron
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23887167

Group type: EXPERIMENTAL
Intervention: Hecolin (recombinant hepatitis E vaccine)
Number of subjects: 14065

Group type: COMPARATOR
Intervention: Placebo (hepatitis B vaccine)
Number of subjects: 14065
Study: 21538380

Group type: EXPERIMENTAL
Intervention: VASP-guided clopidogrel maintenance doses
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group with fixed clopidogrel doses
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: VASP-guided group
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 306
Study: 19183847

Group type: EXPERIMENTAL
Intervention: Curriculum of critical health literacy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (untrained students)
Number of subjects: 45
Study: 16543930

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 45
Study: 15118975

Group type: EXPERIMENTAL
Intervention: Pentasa 4 g/day
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 11509936

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 136
Study: 11301563

Group type: EXPERIMENTAL
Intervention: BMS-188494 (10 mg daily for 2 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BMS-188494 (25 mg daily for 4 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BMS-188494 (50 mg daily for 4 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BMS-188494 (100 mg daily for 4 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BMS-188494 (200 mg daily for 4 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BMS-188494 (all doses)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 7798537

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2848876

Group type: EXPERIMENTAL
Intervention: 90 ppm F and 1% pyrophosphate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 90 ppm F
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (no active agents)
Number of subjects: 15
Study: 31237335

Group type: EXPERIMENTAL
Intervention: LND diet with 0.9% Ca
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: LND diet with 0.7% or more Ca
Number of subjects: 720

Group type: COMPARATOR
Intervention: LND diet with 0.5% Ca
Number of subjects: 720
Study: 28287751

Group type: EXPERIMENTAL
Intervention: Distraction after stress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest after stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distraction after TSST
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest after TSST
Number of subjects: 0
Study: 25265096

Group type: EXPERIMENTAL
Intervention: Seminal plasma
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 100
Study: 24180316

Group type: EXPERIMENTAL
Intervention: Peer-led lifestyle intervention program including eleven small group sessions, two diabetes prevention education sessions, a participant handbook, a participant workbook, and a health education booklet.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Health education booklet containing information on symptoms, complications, and risk factors of T2DM.
Number of subjects: 60
Study: 20460232

Group type: EXPERIMENTAL
Intervention: Fortified milk (5 microg vitamin D3)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control milk (unfortified)
Number of subjects: 73
Study: 18402683

Group type: EXPERIMENTAL
Intervention: Participants in the lifestyle intervention trial
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-participants in the lifestyle intervention trial
Number of subjects: 100
Study: 16537882

Group type: EXPERIMENTAL
Intervention: Intrapleural fibrinolytic therapy
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 575
Study: 14696661

Group type: EXPERIMENTAL
Intervention: Resorbable hydroxyapatite (HA group)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Resorbable membrane (MR group)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Both HA and MR groups combined
Number of subjects: 83
Study: 11139755

Group type: EXPERIMENTAL
Intervention: NSAIDs (ibuprofen 400-800mg, naproxen 550-825mg, ketoprofen 50-75mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine-containing preparations of NSAIDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation therapies with EMG biofeedback and tricyclics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical therapy and acupuncture
Number of subjects: 0
Study: 8864328

Group type: EXPERIMENTAL
Intervention: Pantoprazole 240 mg i.v. once daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1623916

Group type: EXPERIMENTAL
Intervention: Loperamide oxide (1 to 16 mg)
Number of subjects: 10
Study: 6391141

Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg twice weekly for 1 year)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Levamisole among responders
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Placebo among responders
Number of subjects: 251
Study: 31801531

Group type: EXPERIMENTAL
Intervention: Virtual Patients (VP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Small Group Teaching (SGT)
Number of subjects: 57
Study: 29985774

Group type: EXPERIMENTAL
Intervention: Functional warm-up protocol (functional stretching, stability, and mobility exercises)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional dynamic warm-up
Number of subjects: 120
Study: 26825878

Group type: EXPERIMENTAL
Intervention: Liposomal Albendazole (L‐ABZ), 10 mg/kg per day, p.o., b.i.d.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tablet-Albendazole (T‐ABZ), 12-20 mg/kg per day, p.o., b.i.d.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (L‐ABZ and T‐ABZ)
Number of subjects: 60
Study: 24458439

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 166

Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 166
Study: 22476173

Group type: EXPERIMENTAL
Intervention: Fecal leukocytes test performed (Group A)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Fecal leukocytes test and rotavirus/adenovirus test performed (Group B)
Number of subjects: 201
Study: 20578811

Group type: EXPERIMENTAL
Intervention: Tapentadol ER 100 ‐ 250 mg b.i.d.
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Oxycodone CR 20 ‐ 50 mg b.i.d.
Number of subjects: 981

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 981
Study: 18624029

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study: 16116009

Group type: EXPERIMENTAL
Intervention: Infraclavicular block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supraclavicular block
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 12352272

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (15-mg nicotine patch, 4-mg nicotine gum, 10-mg nicotine inhaler, or combination)
Number of subjects: 923

Group type: COMPARATOR
Intervention: Matching placebo products
Number of subjects: 923

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Nicotine group
Number of subjects: 923

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 923

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 923
Study: 10425011

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion during cardiopulmonary bypass (group 2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion during cardiopulmonary bypass (group 1)
Number of subjects: 22
Study: 7750335

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (face‐mask oxygen therapy)
Number of subjects: 100